帕尼单抗对比贝伐珠单抗联合标准化疗对RAS野生型左侧转移性结直肠癌患者总生存的影响:一项随机临床试验
这项在日本197个中心开展的随机、开放标签3期试验纳入823例化疗初治的RAS野生型不可切除转移性结直肠癌患者,比较帕尼单抗或贝伐珠单抗联合mFOLFOX6方案。在左侧肿瘤患者中,帕尼单抗组中位总生存37.9个月 vs 贝伐珠单抗组34.3个月(HR 0.82;95.798%CI 0.68-0.99;P=0.03),总体人群36.2个月 vs 31.3个月(HR 0.84;95%CI 0.72-0.98;P=0.03)。
要点
- 左侧肿瘤患者帕尼单抗组中位总生存37.9个月 vs 贝伐珠单抗组34.3个月(HR 0.82;95.798%CI 0.68-0.99;P=0.03)。
- 总体人群帕尼单抗组中位总生存36.2个月 vs 贝伐珠单抗组31.3个月(HR 0.84;95%CI 0.72-0.98;P=0.03)。
- 左侧肿瘤患者帕尼单抗组客观缓解率80.2% vs 贝伐珠单抗组68.6%(差值11.2%;95%CI 4.4%-17.9%)。
核心结论
- 在RAS野生型转移性结直肠癌患者中,与贝伐珠单抗相比,帕尼单抗联合标准化疗显著改善了左侧肿瘤患者及总体人群的总生存。
研究设计与样本
- 随机、开放标签、3期临床试验,在日本197个中心开展,时间为2015年5月至2022年1月。
- 纳入823例化疗初治的RAS野生型不可切除转移性结直肠癌患者,最终随访日期为2022年1月14日。
- 干预为帕尼单抗(n=411)或贝伐珠单抗(n=412)联合改良氟尿嘧啶、l-亚叶酸钙和奥沙利铂(mFOLFOX6),每14天一次。
- 主要终点为总生存,先在左侧肿瘤参与者中检验,再在总体人群中检验;次要终点包括无进展生存期、缓解率、缓解持续时间和治愈性(定义为R0状态)切除率。
主要发现
- 在按治疗分析人群(n=802;中位年龄66岁;282例[35.2%]女性)中,604例(75.3%)为左侧肿瘤;中位随访61个月。
- 左侧肿瘤患者帕尼单抗组中位总生存37.9个月 vs 贝伐珠单抗组34.3个月(HR 0.82;95.798%CI 0.68-0.99;P=0.03);总体人群分别为36.2个月 vs 31.3个月(HR 0.84;95%CI 0.72-0.98;P=0.03)。
- 左侧肿瘤患者帕尼单抗组中位无进展生存期13.1个月 vs 贝伐珠单抗组11.9个月(HR 1.00;95%CI 0.83-1.20);总体人群12.2个月 vs 11.4个月(HR 1.05;95%CI 0.90-1.24)。
- 左侧肿瘤患者帕尼单抗组缓解率80.2% vs 贝伐珠单抗组68.6%(差值11.2%;95%CI 4.4%-17.9%);总体人群74.9% vs 67.3%(差值7.7%;95%CI 1.5%-13.8%)。
- 左侧肿瘤患者帕尼单抗组中位缓解持续时间13.1个月 vs 贝伐珠单抗组11.2个月(HR 0.86;95%CI 0.70-1.10);总体人群11.9个月 vs 10.7个月(HR 0.89;95%CI 0.74-1.06);左侧肿瘤患者治愈性切除率18.3% vs 11.6%(差值6.6%;95%CI 1.0%-12.3%),总体人群16.5% vs 10.9%(差值5.6%;95%CI 1.0%-10.3%)。
关键数值与推荐
- 常见治疗中出现的不良事件:痤疮样皮疹(帕尼单抗组74.8%;贝伐珠单抗组3.2%)、周围感觉神经病变(帕尼单抗组70.8%;贝伐珠单抗组73.7%)、口腔炎(帕尼单抗组61.6%;贝伐珠单抗组40.5%)。
- 试验注册号:ClinicalTrials.gov NCT02394795。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For patients with RAS wild-type metastatic colorectal cancer, adding anti-epidermal growth factor receptor (anti-EGFR) or anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine, but the optimal targeted therapy has not been defined. OBJECTIVE: To evaluate the effect of adding panitumumab (an anti-EGFR monoclonal antibody) vs bevacizumab (an anti-VEGF monoclonal antibody) to standard first-line chemotherapy for treatment of RAS wild-type, left-sided, metastatic colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, phase 3 clinical trial at 197 sites in Japan in May 2015-January 2022 among 823 patients with chemotherapy-naive RAS wild-type, unresectable metastatic colorectal cancer (final follow-up, January 14, 2022). INTERVENTIONS: Panitumumab (n = 411) or bevacizumab (n = 412) plus modified fluorouracil, l-leucovorin, and oxaliplatin (mFOLFOX6) every 14 days. MAIN OUTCOMES AND MEASURES: The primary end point, overall survival, was tested first in participants with left-sided tumors, then in the overall population. Secondary end points were progression-free survival, response rate, duration of response, and curative (defined as R0 status) resection rate. RESULTS: In the as-treated population (n = 802; median age, 66 years; 282 [35.2%] women), 604 (75.3%) had left-sided tumors. Median follow-up was 61 months. Median overall survival was 37.9 months with panitumumab vs 34.3 months with bevacizumab in participants with left-sided tumors (hazard ratio [HR] for death, 0.82; 95.798% CI, 0.68-0.99; P = .03) and 36.2 vs 31.3 months, respectively, in the overall population (HR, 0.84; 95% CI, 0.72-0.98; P = .03). Median progression-free survival for panitumumab vs bevacizumab was 13.1 vs 11.9 months, respectively, for those with left-sided tumors (HR, 1.00; 95% CI, 0.83-1.20) and 12.2 vs 11.4 months overall (HR, 1.05; 95% CI, 0.90-1.24). Response rates with panitumumab vs bevacizumab were 80.2% vs 68.6%, respectively, for left-sided tumors (difference, 11.2%; 95% CI, 4.4%-17.9%) and 74.9% vs 67.3% overall (difference, 7.7%; 95% CI, 1.5%-13.8%). Median duration of response with panitumumab vs bevacizumab was 13.1 vs 11.2 months for left-sided tumors (HR, 0.86; 95% CI, 0.70-1.10) and 11.9 vs 10.7 months overall (HR, 0.89; 95% CI, 0.74-1.06). Curative resection rates with panitumumab vs bevacizumab were 18.3% vs 11.6% for left-sided tumors; (difference, 6.6%; 95% CI, 1.0%-12.3%) and 16.5% vs 10.9% overall (difference, 5.6%; 95% CI, 1.0%-10.3%). Common treatment-emergent adverse events were acneiform rash (panitumumab: 74.8%; bevacizumab: 3.2%), peripheral sensory neuropathy (panitumumab: 70.8%; bevacizumab: 73.7%), and stomatitis (panitumumab: 61.6%; bevacizumab: 40.5%). CONCLUSIONS AND RELEVANCE: Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, compared with bevacizumab, to standard first-line chemotherapy significantly improved overall survival in those with left-sided tumors and in the overall population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02394795.
引用
- Watanabe J, Muro K, Shitara K, et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2023. PMID: 37071094. doi:10.1001/jama.2023.4428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。